ADL Amdl,

TUSTIN, Calif., April 17 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company. AMDL together with JPI engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. 2007 Operating Strategy. The Company's near and long-term operating strategies focus on (i) obtaining U.S. Food and Drug Administration (FDA) and China's State Food and Drug Administration (SFDA) approval for DR-70( R ), (ii) seeking a large pharmaceutical partner for our CIT technology, (iii) funding the growth of JPI's existing products, and (iv) funding the research and development of new products. "AMDL continues to focus on receiving FDA clearance to market our DR-70( R ) cancer test in the United States which will also strengthen our position in overseas markets. We are also very pleased by the continued outstanding growth at JPI, we anticipate that 2007 will be a great growth year for the Company," said Gary Dreher, AMDL CEO. Comparison of 2006 to 2005. The results of operations for the years ended December 31, 2006 and 2005 are not comparable due to the acquisition of JPI on September 28, 2006. JPI's results of operations have been included in the Company's consolidated results since the date of acquisition. 2006 Net Revenues. The Company generated aggregate net revenues of $2,103,936 from product sales compared to revenues from product sales of $67,565 in the prior year period, an increase of $2,036,371. $2,032,881 of these net revenues was contributed by JPI during the last three months of 2006 following the closing of the acquisition. There was a nominal increase in revenues from AMDL's traditional products of approximately $3,500 for fiscal year 2006 over fiscal 2005. 2006 Net Loss and Net Loss Per Share. For fiscal year 2006 our consolidated net loss was $5,867,428 or ($0.83) per share as compared to a net loss of $2,506,665 or ($0.50) per share in fiscal year 2005. The increase in the net loss per share was significantly adversely affected by the issuance of common stock for consulting and investor relations services ($1,054,405) and charges for compensatory options to officers, directors and employees ($2,397,700). The significant non-cash expense associated with the compensatory options were due to the Company's adoption of the new rules related to option accounting in FASB 123R. The non-cash expenses were offset in part by the acquisition of JPI which contributed net income of $435,814 for the three months and year ended December 31, 2006. 2006 Assets and Liabilities. At December 31, 2006, the Company had total assets of $19,240,613 compared to total assets of $3,181,841 at December 31, 2005. The primary reason for the increase was the acquisition of JPI which increased our assets by $15,224,675. Cash and cash equivalents was $1,584,973 as of December 31, 2006, an increase of $186,881 (13.4%) from the $1,398,092 cash on hand as of December 31, 2005. For the year ended December 31, 2006, cash used in operations was $1,938,285. The major components were the net loss of $5,867,428 offset by non-cash expense of $2,397,700 related to the fair value of options granted to employees and directors, $1,054,405 related to common stock issued to consultants for services and $310,372 for depreciation and amortization. Net cash of $2,572,051 was provided by a private placement of common stock in December 2006 and $306,086 provided by the exercise of warrants and options during the year ended December 31, 2006. Cash used in investing activities during fiscal year 2006 was $731,140, the majority of which was comprised of the purchase of product licenses and the cash paid, net of cash acquired, in the JPI acquisition. About AMDL AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright